The DOI matches its Crossref record; 176 of the 177 references it cites were found in a registry or an index.
From tumour heterogeneity to advances in precision treatment of colorectal cancer
Open accessAbstract
In recent years, the high heterogeneity of colorectal cancer (CRC) has become evident. Hence, biomarkers need to be developed that enable the stratification of patients with CRC into different prognostic subgroups and in relation to response to therapies, according to the distinctive tumour biology. Currently, only RAS-mutation status is used routinely as a negative predictive marker to avoid treatment with anti-EGFR agents in patients with metastatic CRC, and mismatch-repair status can guide the use of adjuvant chemotherapy in patients with early stage colon cancer. Advances in molecular biology over the past decade have enabled a better understanding of the development of CRC, as well as the more-precise use of innovative targeted therapies for this disease, and include three fundamental achievements. First, the availability of large databases to capture and store the genomic landscape of patients with CRC, providing information on the genes that are frequently deregulated in CRC. Second, the possibility of using gene-expression profiling to differentiate the subtypes of CRC into prognostic groups. Third, results from highly sensitive next-generation sequencing analyses have led to an appreciation of the extensive intratumoural heterogeneity of CRC. Herein, we discuss these advances and place them into the clinical context, and present the novel targets and therapeutic opportunities that are on the horizon.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“5-FU/LV is useful in palliative therapy for mCRC, but the development of effective doublet combination therapy regimens, including FOLFOX (folinic acid (leucovorin), 5-FU, oxaliplatin) and FOLFIRI (leucovorin, 5-FU, irinotecan) [10], resulted in significant survival advantages.”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170
Self-citationA human colon cancer cell capable of initiating tumour growth in immunodeficient mice
O'Brien, C. A., Pollett, A. F., Gallinger, S., & Dick, J. E. (2006) · Nature · doi:10.1038/nature05372 · Cited by 4,174
Identification and expansion of human colon-cancer-initiating cells
Ricci‐Vitiani, L., Lombardi, D. G., Pilozzi, E., Biffoni, M., Todaro, M., Peschle, C., & Maria, R. D. (2006) · Nature · doi:10.1038/nature05384 · Cited by 4,001
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Cited by
Sorted by citations
Current understanding of the human microbiome
Gilbert, J. A., Blaser, M. J., Caporaso, J. G., Jansson, J. K., Lynch, S. V., & Knight, R. (2018) · Nature Medicine · doi:10.1038/nm.4517 · Cited by 2,609
5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future
Vodenkova, S., Buchler, T., Cervena, K., Veskrnova, V., Vodicka, P., & Vymetalkova, V. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107447 · Cited by 956
Ooft, S. N., Weeber, F., Dijkstra, K. K., McLean, C. M., Kaing, S., van Werkhoven, E., Schipper, L., Hoes, L., Vis, D. J., van de Haar, J., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aay2574 · Cited by 813
Genome doubling shapes the evolution and prognosis of advanced cancers
Bielski, C. M., Zehir, A., Penson, A. V., Donoghue, M. T. A., Chatila, W. K., Armenia, J., Chang, M. T., Schram, A. M., Jonsson, P., Bandlamudi, C., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0165-1 · Cited by 654
Clinical management of metastatic colorectal cancer in the era of precision medicine
Ciardiello, F., Ciardiello, D., Martini, G., Napolitano, S., Tabernero, J. M., & Cervantes, A. M. R. (2022) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21728 · Cited by 556
The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy
Yuan, J., Dong, X., Yap, J., & Hu, J. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00949-4 · Cited by 516
Host–microbiota maladaptation in colorectal cancer
Janney, A., Powrie, F., & Mann, E. H. (2020) · Nature · doi:10.1038/s41586-020-2729-3 · Cited by 445
New insights into the role of EMT in tumor immune escape
Terry, S., Savagner, P., Ortiz‐Cuaran, S., Mahjoubi, L., Saintigny, P., Thiery, J., & Chouaib, S. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12093 · Cited by 414
“While the majority of colon carcinomas and corresponding cell lines appear more Epi on average, some tumors do exhibit Mes-like phenotypes likely corresponding to the newly established Mes molecular subtype (Punt et al., 2017).”
BackgroundWu, Y., Yang, X., Chen, Z., Tian, L., Jiang, G., Chen, F., Li, J., An, P., Lu, L., Luo, N., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1014-2 · Cited by 390
Integrated Omics of Metastatic Colorectal Cancer
Li, C., Sun, Y.-D., Yu, G.-Y., Cui, J.-R., Lou, Z., Zhang, H., Huang, Y., Bai, C.-G., Deng, L.-L., Liu, P., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.002 · Cited by 297
Sirinukunwattana, K., Domingo, E., Richman, S. D., Redmond, K. L., Blake, A., Verrill, C., Leedham, S. J., Chatzipli, A., Hardy, C., Whalley, C. M., et al. (2021) · Gut · doi:10.1136/gutjnl-2019-319866 · Cited by 264
Prognostic and Predictive Molecular Biomarkers for Colorectal Cancer: Updates and Challenges
Koncina, E., Haan, S., Rauh, S., & Letellier, E. (2020) · Cancers · doi:10.3390/cancers12020319 · Cited by 272
“This mutation is typically mutually exclusive with other RAS mutations [40,69].”
BackgroundLenz, H.-J., Ou, F.-S., Venook, A. P., Hochster, H. S., Niedzwiecki, D., Goldberg, R. M., Mayer, R. J., Bertagnolli, M. M., Blanke, C. D., Zemla, T., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02258 · Cited by 246
“These insights have the potential to help treating physicians to use an individual’s tumor molecular makeup to predict likely sensitivity and resistance to targeted therapies.(9,10) ASSOCIATED CONTENT See accompanying Editorial on page 1847 Appendix Data Supplements Author affiliations and support information (if appl…”
BackgroundPostel, M., Roosen, A., Laurent‐Puig, P., Taly, V., & Renault, S. (2017) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2018.1400384 · Cited by 255
“Third, presence of multiple tumor sites also complicates the characterization of the patient pathology [14].”
BackgroundMartinelli, E., Ciardiello, D., Martini, G., Troiani, T., Cardone, C., Vitiello, P. P., Normanno, N., Rachiglio, A. M., Maiello, E., Latiano, T., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.10.007 · Cited by 225
“Intratumor genetic heterogeneity refers to the concept that in a single tumor, different cancer cell clones, carrying different molecular alterations, coexist.(30) Recently, greater attention has been focused on the issue of tumor heterogeneity, since the presence of cancer cell clones with different mutations could c…”
Backgroundten Hoorn, S., de Back, T. R., Sommeijer, D. W., & Vermeulen, L. (2022) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djab106 · Cited by 203
“CRC is a highly heterogeneous disease with respect to clinical and biological features, resulting in striking differences in disease progression and treatment response (2).”
BackgroundSelf-citationLiu, Z., Guo, C., Dang, Q., Wang, L., Liu, L., Weng, S., Xu, H., Lu, T., Sun, Z., & Han, X. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103750 · Cited by 185
Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors
Nayyar, G., Chu, Y., & Cairo, M. S. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00051 · Cited by 180
“This heterogeneity could be due to differences in evolution of these tumors caused by varying gene profile signature, different mutations and involvement of different cell signaling pathways (2, 3).”
BackgroundColorectal Cancers: An Update on Their Molecular Pathology
Inamura, K. (2018) · Cancers · doi:10.3390/cancers10010026 · Cited by 182
Tang, X., Tan, L., Shi, K., Peng, J., Xiao, Y., Li, W., Chen, L., Yang, Q., & Qian, Z. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.05.011 · Cited by 147
Genetic and epigenetic alterations of colorectal cancer
Hong, S. N. (2018) · Intestinal Research · doi:10.5217/ir.2018.16.3.327 · Cited by 144
“In human MSI-H CRC and cancer cell lines with MSI-H, APC , KRAS , and TP53 have been found to be mutated.(20,21) MSI-H tumors have been found in about 15% of sporadic CRCs.”
BackgroundRole of Epithelial to Mesenchymal Transition in Colorectal Cancer
Lu, J., Kornmann, M., & Traub, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914815 · Cited by 156
“[3,9,18,28,32,63–65].”
Molecular subtypes in cancers of the gastrointestinal tract
Bijlsma, M. F., Sadanandam, A., Tan, P. B. O., & Vermeulen, L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.33 · Cited by 134
Self-citationZhao, G., Yuan, H., Qin, L., Zhang, J., Guo, Y., Feng, T., Gu, R. C., Ou, D., Li, S., Li, K., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01096-7 · Cited by 131
Lactate controls cancer stemness and plasticity through epigenetic regulation
Nguyen, N. B., Gevers, S., Kok, R. N. U., Burgering, L. M., Neikes, H. K., Akkerman, N., Betjes, M. A., Ludikhuize, M. C., Gulersonmez, C. M. C., Stigter, E. C. A., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.01.002 · Cited by 135
Du, F., Chen, J., Liu, H., Cai, Y., Cao, T., Han, W., Yi, X., Qian, M., Tian, D., Nie, Y., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1481-9 · Cited by 117
Yuan, Q., Deng, D., Chen, P., Ren, J., Wei, T., Wu, Z., Zhang, B., Li, S., Yin, P., & Shang, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.951137 · Cited by 118
“The response of patients to chemotherapy and immunotherapy and their prognosis are intimately associated with tumour heterogeneity (7, 8).”
BackgroundStrating, E., Verhagen, M. P., Wensink, G. E., Dünnebach, E., Wijler, L. A., Aranguren, I., la Cruz, A. S. D., Peters, N. A., Hageman, J. H., van der Net, M. C., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1053920 · Cited by 122
“Some of this information has been used to devise more personalized strategies of (targeted) anti-cancer treatment (8, 9).”
MethodIntegrated approaches for precision oncology in colorectal cancer: The more you know, the better
Andrei, P., Battuello, P., Grasso, G., Rovera, E., Tesio, N., & Bardelli, A. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.04.007 · Cited by 116
Mapping the spreading routes of lymphatic metastases in human colorectal cancer
Zhang, C., Zhang, L., Xu, T., Xue, R., Yu, L., Zhu, Y.-L., Wu, Y., Zhang, Q., Li, D., Shen, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15886-6 · Cited by 112
Ni, W., Mo, H., Liu, Y., Xu, Y., Qin, C., Zhou, Y., Li, Y., Li, Y., Zhou, A., Yao, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.05.012 · Cited by 110
Kumar, S., & Agnihotri, N. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.10.182 · Cited by 109
Prognostic Cancer Gene Expression Signatures: Current Status and Challenges
Qian, Y., Daza, J., Itzel, T., Betge, J., Zhan, T., Marmé, F., & Teufel, A. (2021) · Cells · doi:10.3390/cells10030648 · Cited by 112
“However, the selection of patients is currently suboptimal due to a lack of established biomarkers (except for mismatch repair deficiency), leading to either over- or undertreatment [45].”
BackgroundCCNA2 acts as a novel biomarker in regulating the growth and apoptosis of colorectal cancer
Gan, Y., Li, Y., Li, T., Shu, G., & Yin, G. (2018) · Cancer Management and Research · doi:10.2147/cmar.s176833 · Cited by 108
“Due to the high heterogeneity of CRC, researchers are exploring biomarkers that could indicate the specific cancer subtype and prognosis of CRC in recent decades.(20) Until now, several biomarkers have been discovered in a wide range of cancers.”
BackgroundGmeiner, W. H., & Okechukwu, C. C. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2022.136 · Cited by 123
Zhao, G., Wang, Q., Zhang, Y., Gu, R. C., Liu, M., Li, Q., Zhang, J., Yuan, H., Feng, T., Ou, D., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-022-05508-y · Cited by 103
“Accumulating evidence has indicated that CRC is a highly heterogeneous disease characterized by extensively dysregulated gene expression and mutational burdens [5, 6].”
BackgroundCheng, X., Feng, H., Wu, H., Jin, Z., Shen, X., Kuang, J., Huo, Z., Chen, X., Gao, H., Ye, F., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.05.046 · Cited by 102
Characterization of a p53/miR-34a/CSF1R/STAT3 Feedback Loop in Colorectal Cancer
Shi, X., Kaller, M., Rokavec, M., Kirchner, T., Horst, D. A., & Hermeking, H. (2020) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2020.04.002 · Cited by 102
“More than 50% of colorectal cancer (CRC) patients will develop liver metastases, leading to ineffective chemotherapy and increased mortality.(2,3) Epithelialmesenchymal transition (EMT) of primary tumor cells is one of the first steps of the metastatic cascade.”
BackgroundHamada, T., Nowak, J. A., Milner, D. A., Song, M., & Ogino, S. (2019) · The Journal of Pathology · doi:10.1002/path.5236 · Cited by 100
Therapeutic potential of FLANC, a novel primate-specific long non-coding RNA in colorectal cancer
Pichler, M., Rodriguez‐Aguayo, C., Nam, S. Y., Dragomir, M. P., Bayraktar, R., Anfossi, S., Knutsen, E., Ivan, C., Fuentes‐Mattei, E., Lee, S. K., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-318903 · Cited by 96
MYC-Activated LncRNA MNX1-AS1 Promotes the Progression of Colorectal Cancer by Stabilizing YB1
Wu, Q., Luo, X.-J., Liu, J., Lu, Y., Wang, Y., Qi, J., Liu, Z., Huang, Q., Liu, Z.-K., Lu, J.-B., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3747 · Cited by 96
“Recently, molecular stratification has been implemented in clinical practice to identify subgroups who may benefit from novel treatments, especially among patients with metastatic colorectal cancer who lack treatment options (1, 2, 4).”
BackgroundPeritoneal Metastases From Colorectal Cancer: Defining and Addressing the Challenges
Kranenburg, O., der Speeten, K. V., & de Hingh, I. H. J. T. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.650098 · Cited by 99
“The most effective regimens have prolonged median overall survival to more than 2 years (65).”
BackgroundHuang, Y., Liu, N., Liu, J., Liu, Y., Zhang, C., Long, S., Luo, G., Zhang, L., & Zhang, Y. (2019) · Cell Cycle · doi:10.1080/15384101.2019.1688951 · Cited by 94
“P53 mutations found in 50% of the tumors left the growth out of control, promoting malignant development of the tumor [39,40], and were likely to be a clinical indicator of tumor [41,42].”
BackgroundZhou, Y., Shao, Y., Hu, W., Zhang, J., Shi, Y., Kong, X., & Jiang, J. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-01049-1 · Cited by 93
Xu, H., Wang, T., Yang, C., Li, X., Liu, G., Yang, Z., Singh, P. K., Krishnan, S., & Ding, D. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201707140 · Cited by 93
Gu, X., Wei, Y., Fan, Q., Sun, H., Cheng, R., Zhong, Z., & Deng, C. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.03.005 · Cited by 93
“Colorectal cancer remains one of the leading causes of cancer-related death worldwide [1,2].”
BackgroundExploring and modelling colon cancer inter-tumour heterogeneity: opportunities and challenges
Buikhuisen, J. Y., Torang, A., & Medema, J. P. (2020) · Oncogenesis · doi:10.1038/s41389-020-00250-6 · Cited by 96
“Administration of chemotherapy to stage III patients increases overall survival, but the bene fi t for high-risk stage II patients has been called into question 9,10 .”
BackgroundInfluentialKoustas, E., Karamouzis, M. V., Mihailidou, C., Schizas, D., & Papavassiliou, A. G. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.03.023 · Cited by 79
Heterogeneous pathway activation and drug response modelled in colorectal-tumor-derived 3D cultures
Schumacher, D., Andrieux, G., Boehnke, K., Keil, M., Silvestri, A., Silvestrov, M., Keilholz, U., Haybaeck, J., Erdmann, G., Sachse, C., et al. (2019) · PLoS Genetics · doi:10.1371/journal.pgen.1008076 · Cited by 79
“Mutations in RAS gene family members or BRAF turn out to be negative predictors for anti-receptor tyrosine kinase therapies [5], while at least a subset of RAS wild-type tumors shows a therapeutic response [6].”
BackgroundJiang, C., Liu, Y., Wen, S., Xu, C., & Gu, L. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105644 · Cited by 80
Lin, D., Fan, W., Zhang, R., Zhao, E., Li, P., Zhou, W., Peng, J., & Li, L. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02952-w · Cited by 80
“However, the relapse and death risks may vary vastly even in patients with the same clinicopathological features due to the high level of molecular heterogeneity [4, 5].”
BackgroundBodei, L., Schöder, H. M., Baum, R. P., Herrmann, K., Strosberg, J., Caplin, M. E., Öberg, K., & Modlin, I. M. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30323-5 · Cited by 79
Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment
Gmeiner, W. H. (2024) · Cancers · doi:10.3390/cancers16051029 · Cited by 78
“5-FU/LV is useful in palliative therapy for mCRC, but the development of effective doublet combination therapy regimens, including FOLFOX (folinic acid (leucovorin), 5-FU, oxaliplatin) and FOLFIRI (leucovorin, 5-FU, irinotecan) [10], resulted in significant survival advantages.”
BackgroundMicroenvironment-triggered multimodal precision diagnostics
Hao, L., Rohani, N., Zhao, R. T., Pulver, E. M., Mak, H. H., Kelada, O. J., Ko, H., Fleming, H. E., Gertler, F. B., & Bhatia, S. N. (2021) · Nature Materials · doi:10.1038/s41563-021-01042-y · Cited by 76
Patient-derived mini-colons enable long-term modeling of tumor–microenvironment complexity
Lorenzo‐Martín, L. F., Broguière, N., Langer, J., Tillard, L., Nikolaev, M., Coukos, G., Homicskó, K., & Lütolf, M. P. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02301-4 · Cited by 78
“Despite these efforts, ex vivo modeling of CRC has shown relatively limited translational success in the clinical scenario so far 6,7 , indicating that the nature of current in vitro systems is still overly simplistic 4,8,9 .”
Wang, L. Y., Shang, Z., Zhou, Y., Hu, X., Chen, Y., Fan, Y., Wei, X., Wu, L. L., Liang, Q., Zhang, J., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0242-x · Cited by 75
He, J., Wei, Q., Wang, S., Hua, S., & Zhou, M. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120734 · Cited by 71
Ribosome Biogenesis Alterations in Colorectal Cancer
Nait-Slimane, S., Marcel, V., Fenouil, T., Catez, F., Saurin, J., Bouvet, P., Diaz, J., & Mertani, H. C. (2020) · Cells · doi:10.3390/cells9112361 · Cited by 77
“Among the genetic mutations, the Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) gene mutated in 40% and the BRAF gene mutated in 10% of CRC patients are useful predictive markers for metastatic disease [2,18,19].”
BackgroundAdvances in colon cancer research: in vitro and animal models
Lannagan, T. R. M., Jackstadt, R., Leedham, S. J., & Sansom, O. J. (2021) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2020.12.003 · Cited by 74
“While the use of EGFR inhibitor depends on the mutation status of KRAS and BRAF [5], VEGFR inhibitors are routinely applied for stage IV patients [6].”
BackgroundMacromolecular Poly(N‐isopropylacrylamide) (PNIPAM) in Cancer Treatment and Beyond
Throat, S., & Bhattacharya, S. (2024) · Advances in Polymer Technology · doi:10.1155/2024/1444990 · Cited by 78
Thomsen, M., Skovlund, E., Sørbye, H., Bolstad, N., Nustad, K., Glimelius, B. L. G., Pfeiffer, P., Kure, E. H., Johansen, J. S., Tveit, K. M., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0115-9 · Cited by 70
“1 162 (29) 155 (28) 145 (29) 10 (20) 126 (29) 119 (29)”
Ge, W., Hu, H., Cai, W., Xu, J., Hu, W., Weng, X., Qin, X., Huang, Y., Han, W., Hu, Y., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32775 · Cited by 68
“Single genetic characteristics, such as DNA mismatch repair (MMR) deficiency status, RAS-mutation or BRAFmutation, have been proposed as prognostic biomarkers.(1,5) Somatic mutational profiling based molecular signatures have been developed to detecting patients at a high risk of recurrence.”
BackgroundThe effect of miRNA and autophagy on colorectal cancer
Long, J., He, Q., Yin, Y., Lei, X., Li, Z., & Zhu, W. (2020) · Cell Proliferation · doi:10.1111/cpr.12900 · Cited by 69
Song, D., Guo, M. Z., Xu, S., Xiaotian, S., Bai, B., Li, Z., Chen, J., An, Y., Nie, Y., Wu, K., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01951-5 · Cited by 65
“and advanced metastatic CRC remains incurable [3, 5].”
Bolhuis, K., Kos, M., van Oijen, M. G. H., Swijnenburg, R., & Punt, C. J. A. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.09.037 · Cited by 66
Self-citationTumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal Cancer
Masugi, Y., Nishihara, R., Hamada, T., Song, M., da Silva, A., Kosumi, K., Gu, M., Shi, Y. X., Li, W., Liu, L., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0122 · Cited by 61
Tabernero, J. M., Cutsem, E. V., Garralda, E., Tai, D. W.-M., de Braud, F., Geva, R., van Bussel, M. T. J., Dotti, K. F., Élez, E., Miguel, M. J. D., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyad007 · Cited by 67
Hamada, T., Soong, T. R., Masugi, Y., Kosumi, K., Nowak, J. A., da Silva, A., Mu, X. J., Twombly, T. S., Koh, H., Yang, J., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1442999 · Cited by 60
DNA methylation and chromatin modifiers in colorectal cancer
Vymetalkova, V. P., Vodička, P., Vodenková, S., Alonso, S., & Schneider‐Stock, R. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2019.04.002 · Cited by 58
Chakrabarti, S., Xie, H., Urrutia, R. A., & Mahipal, A. (2020) · Cancers · doi:10.3390/cancers12102808 · Cited by 60
“Furthermore, tumor sequencing might not detect all relevant mutations because of intratumor heterogeneity [42] and may not capture subsequently emerging mutations as a result of treatment [43].”
BackgroundChimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment
Zhao, Z., Xiao, X., Saw, P. E., Wu, W., Huang, H., Chen, J., & Nie, Y. (2019) · Science China Life Sciences · doi:10.1007/s11427-019-9665-8 · Cited by 56
Sun, Z., Zhao, M., Wang, W., Hong, L., Wu, Z., Luo, G., Lu, S., Tang, Y., Li, J., Wang, J., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2022.216032 · Cited by 57
Immune Resistance and EGFR Antagonists in Colorectal Cancer
Giordano, G., Remo, A., Porrás, A., & Pancione, M. (2019) · Cancers · doi:10.3390/cancers11081089 · Cited by 54
“In fact, the inhibition of VEGFR2 in xenograft assays resistant to EGFR blockade was able to reduce tumor growth [4,14,23].”
BackgroundNew insights into the epigenetics of inflammatory rheumatic diseases
Ballestar, E., & Li, T. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.147 · Cited by 56
Tumor-associated macrophages (TAMs) depend on MMP1 for their cancer-promoting role
Yu, J., Xu, Z., Guo, J., Yang, K., Zheng, J., & Sun, X. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00730-7 · Cited by 53
“Although great progress has been achieved in early detection and multimodality treatment of CRC [2, 3], most advanced CRC patients have a poor prognosis.”
BackgroundIntegrated multi-omics characterization of KRAS mutant colorectal cancer
Chong, W., Zhu, X., Ren, H., Ye, C., Xu, K., Wang, Z., Jia, S., Shang, L., Li, L., & Chen, H. (2022) · Theranostics · doi:10.7150/thno.73089 · Cited by 56
“CRC is widely considered a heterogeneous disease, with multiple gene alterations and numerous pathways involved in its pathogenesis [2].”
BackgroundShimura, T., Sharma, P., Sharma, G. G., Banwait, J. K., & Goel, A. (2021) · Scientific Reports · doi:10.1038/s41598-021-87283-y · Cited by 53
Liu, Z., Xu, H., Weng, S., Ren, Y., & Han, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.828330 · Cited by 52
“Mounting evidence have established the links between cancer stemness and intratumoral heterogeneity across cancer (2, 9, 10, 18), and a theory believes cancer stemness is the origin of intratumoral heterogeneity and plasticity (19).”
BackgroundMethodPatient-derived organoids as a platform for drug screening in metastatic colorectal cancer
He, X., Jiang, Y. J., Zhang, L., Li, Y., Hu, X., Hua, G., Cai, S., Mo, S., & Peng, J. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1190637 · Cited by 56
Role of COL6A3 in colorectal cancer
Liu, W., Li, L., Ye, H., Tao, H., & He, H. (2018) · Oncology Reports · doi:10.3892/or.2018.6331 · Cited by 54
“The application of NGS has led to the identification of several mutated genes in CRC that predict survival outcomes (2,27).”
BackgroundFathi, M., Pustokhina, I., Kuznetsov, S. V., Khayrullin, M., Hojjat‐Farsangi, M., Karpisheh, V., Jalili, A., & Jadidi‐Niaragh, F. (2021) · IUBMB Life · doi:10.1002/iub.2461 · Cited by 53
“Similarly, liver metastases in many CRC patients with unsuccessful treatment result in higher mortality.(14,15) Mounting studies have demonstrated the role of the tumor microenvironment in cancer treatments, particularly checkpoint inhibitor-based immunotherapy.”
BackgroundChemistry of Fluorinated Pyrimidines in the Era of Personalized Medicine
Gmeiner, W. H. (2020) · Molecules · doi:10.3390/molecules25153438 · Cited by 65
“FPs cont nue to be he most widely used drugs for CRC treatment and are h ghly relevant for cancer treatment in the era of personalized medicine [99].”
BackgroundDzobo, K., Senthebane, D. A., Thomford, N. E., Rowe, A., Dandara, C., & Parker, M. I. (2018) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2017.0174 · Cited by 54
“Currently, biomarkers obtained using cancer cells are obtained from the primary tumor direct targeted therapy (Punt et al., 2017; Turner and Reis-Filho, 2012; Zhang et al., 2016a).”
Novel digital signatures of tissue phenotypes for predicting distant metastasis in colorectal cancer
Sirinukunwattana, K., Snead, D. R. J., Epstein, D. B. A., Aftab, Z., Mujeeb, I., Tsang, Y. W., Cree, I. A., & Rajpoot, N. (2018) · Scientific Reports · doi:10.1038/s41598-018-31799-3 · Cited by 53
Höppener, D. J., Nierop, P. M. H., Herpel, E., Rahbari, N. N., Doukas, M., Vermeulen, P., Grünhagen, D. J., & Verhoef, C. K. (2019) · Clinical & Experimental Metastasis · doi:10.1007/s10585-019-09975-0 · Cited by 51
Tong, Y., Huang, Y., Zhang, Y., Zeng, X., Yan, M., Xia, Z., & Lai, D. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03796-4 · Cited by 51
Şahin, İ. H., & Klostergaard, J. (2021) · JCO Oncology Practice · doi:10.1200/op.21.00160 · Cited by 54
Detection and clinical significance of circulating tumor cells in colorectal cancer
Jiang, M., Jin, S., Han, J., Li, T., Shi, J., Zhong, Q., Li, W., Tang, W., Huang, Q., & Zong, H. (2021) · Biomarker Research · doi:10.1186/s40364-021-00326-4 · Cited by 54
“Early detection and precision treatment are keys to improving the prognosis of CRC patients [3].”
BackgroundForkhead box K2 promotes human colorectal cancer metastasis by upregulating ZEB1 and EGFR
Du, F., Qiao, C., Li, X., Chen, Z., Liu, H., Wu, S., Hu, S., Qiu, Z., Qian, M., Tian, D., et al. (2019) · Theranostics · doi:10.7150/thno.31716 · Cited by 50
“which have improved the survival rate of CRC at the early stage, knowledge of the underlying molecular mechanisms and therapeutics for advanced metastatic CRC are lacking [2, 3].”
BackgroundPatient‐derived organoids as a preclinical platform for precision medicine in colorectal cancer
Cho, Y., Min, D., Kim, H., An, Y., Kim, S., Youk, J., Chun, J., Im, J. P., Song, S., Ju, Y. S., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13144 · Cited by 49
Hu, A., Wang, H., Xu, Q., Pan, Y., Jiang, Z., Li, S., Qu, Y., Hu, Y., Wu, H., & Wang, X. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102959 · Cited by 52
“The current methods for CRC diagnosis and treatment, such as colonoscopy, surgery, chemotherapy, radiotherapy and targeted therapy, have various drawbacks and limitations, such as toxicity, resistance, low efficacy and narrow applicability [2 – 4].”
MethodSmoking and Risk of Colorectal Cancer Sub-Classified by Tumor-Infiltrating T Cells
Hamada, T., Nowak, J. A., Masugi, Y., Drew, D. A., Song, M., Cao, Y., Kosumi, K., Mima, K., Twombly, T. S., Liu, L., et al. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy137 · Cited by 49
Vodička, P., Urbanová, M., Makovický, P., Tomášová, K., Kroupa, M., Štětina, R., Opattová, A., Kostovcikova, K., Siskova, A., Schneiderová, M., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072473 · Cited by 48
Tieng, F. Y. F., Baharudin, R., Abu, N., Yunos, R. I. M., Lee, L., & Mutalib, N. A. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00135 · Cited by 45
Orally Administrable Therapeutic Nanoparticles for the Treatment of Colorectal Cancer
Ying, K., Bai, B., Gao, X., Xu, Y., Wang, H., & Xie, B. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.670124 · Cited by 46
Chakraborty, J., Chakraborty, S., Chakraborty, S., & Narayan, M. (2023) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2023.194988 · Cited by 47
Tang, B., Zhu, J., Liu, F., Ding, J., Wang, Y., Fang, S., Zheng, L., Qiu, R., Chen, M., Shu, G., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04827-4 · Cited by 44
“As a highly molecular heterogeneous disease, the underlying molecular mechanism of CRC is still poorly understood [21].”
Sun, H., Sun, L., Ke, X., Liu, L., Li, C., Jin, B., Wang, P., Jiang, Z., Zhao, H., Yang, Z., et al. (2023) · Advanced Science · doi:10.1002/advs.202304460 · Cited by 47
Liu, J., Liu, X., Yuan, Y., Li, Q., Chang, B., Xu, L., Cai, B., Qi, C., Li, C., Jiang, X., et al. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b05232 · Cited by 44
Gulhati, P., Raghav, K. P. S., Shroff, R. T., Varadhachary, G. A., Javle, M. M., Qiao, W., Wang, H., Morris, J. S., Wolff, R. A., & Overman, M. J. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0568 · Cited by 44
“We evaluated several key mutational hotspots associated with resistance to EGFR blockade in metastatic CRC [21].”
Background
Metadata
- Authors
- Punt, C. J. A., Koopman, M., & Vermeulen, L.
- Affiliations
- Amsterdam UMC Location University of Amsterdam (NL)
- University Medical Center Utrecht (NL)
- Corresponding author
- Punt, Cornelis J. A.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2016-12-06
- Volume
- 14
- Issue
- 4
- Pages
- 235-246
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W2560375214
- Cited by
- 654
- References
- 177
- Citations by year
- 2026: 38 · 2025: 41 · 2024: 87 · 2023: 79 · 2022: 88 · 2021: 96 · 2020: 83 · 2019: 57 · 2018: 56 · 2017: 28
- FWCI
- 4.73
- Type
- journal article
- Language
- en
- Open access
- green
- pure.amsterdamumc.nl
- Licence
- Locations
- Nature Reviews Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Utrecht University Repository (Utrecht University) (submittedVersion)
- Funders
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
- Maag Lever Darm Stichting (MLDS-CDG 14-03)
- H2020 European Research Council (638193)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Keywords
- colorectal cancer, intratumoral heterogeneity, precision medicine, targeted therapy, gene expression profiling, tumor subtypes, prognostic factors, predictive biomarkers, RAS mutations, DNA mismatch repair, anti-EGFR therapy, adjuvant chemotherapy, next-generation sequencing
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Forecasting, Humans, Immunotherapy, Neoplasm Metastasis, Neoplasm Proteins, Neoplasm Staging, Prognosis, Quality of Health Care, Colorectal Neoplasms, Treatment Outcome, Genetic Heterogeneity, Therapies, Investigational, Proto-Oncogene Proteins B-raf, DNA Mismatch Repair, Early Detection of Cancer, Precision Medicine, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
